Glioblastoma (GBM) is among the most formidable of all human cancers. Despite decades of effort, patient outcomes have changed little. The reasons are now all…
Read More
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Trogenix has developed a platform for generating ‘synthetic super-enhancers’ that…
Read More
Newco Trogenix Ltd. has emerged from incubation and raised £70 million (US$94.1 million) in a series A, as it prepares the ground for a U.S/U.K.…
Read More
Less than a year after leaving stealth mode, Trogenix has raised $95 million in a Series A round aimed at advancing its “Trojan horse” approach…
Read More
Cancer is no longer seen as a simple disease of unchecked cell growth, but as a complex, adaptive ecosystem shaped by genetic mutations, immune evasion,…
Read More
Edinburgh-based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumour Amy Brown…
Read More
Trogenix comes out of stealth, unveiling its innovative Synthetic Super-Enhancers (SSE) platform, Odysseus, to develop highly selective, one-time cancer treatments. Equipped with £15 million ($19…
Read More
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain…
Read More